5th Oligonucleotides for CNS Summit
The Oligonucleotides for CNS Summit returns for its 5th year to address key challenges in durability, scalability, potency and CNS tropism, that lie at the core of developing new antisense and RNA therapies.
Over the 3-day agenda, you’ll join a select group of industry-leading biologists, chemists, C-level executives, platform tech experts, DMPK and clinical pharmacologists, all tackling the unique challenges of CNS delivered ASOs, siRNAs, miRNAs and saRNAs.
This year’s sessions will focus on:
- Reviewing innovative strategies for assessing ASO and siRNA delivery, and distribution in the CNS
- Discovering novel conjugates beyond antibodies and TfR1, and optimize oligonucleotide chemistry, to enhance potency, safety and stability
- Advancing more efficient delivery systems to ensure target-specific CNS tropism with minimum efficacious doses
- Exploring the latest in vitro and in vivo models to test new compounds and optimize CNS biomarkers to assess oligonucleotide efficacy
Plus, we have some new additions for 2025’s agenda including: regulator presence from a former FDA employee, a two tracked workshop day designed for chemists and biologist, 10 new presenting companies including Denali Therapeutics, Alnylam Pharmaceuticals and Novo Nordisk, and much more.
You won’t want to miss out on this unique summit that is redefining the landscape of oligonucleotide research.
Interested in learning more? View the full agenda here: https://ter.li/2djbus
